FierceBiotech Feb 3, 2026 Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
FierceBiotech Feb 3, 2026 NMD flunks rare disease trial but flexes secondary data to accelerate program
FierceBiotech Feb 2, 2026 Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
FierceBiotech Feb 2, 2026 China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
FierceBiotech Feb 2, 2026 Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
FierceBiotech Feb 2, 2026 Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
FierceBiotech Feb 2, 2026 AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection
FierceBiotech Jan 30, 2026 Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’